Canagliflozin-induced pancreatitis: A rare side effect of a new drug

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 991-994

  Chowdhary, Mudit ^a   Kabbani, Ahmad A ^a   Chhabra, Akansha ^b  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Canagliflozin; Drug induced pancreatitis; Invokana; Pancreatitis; SGLT 2 inhibitor

Indexed keywords

AMYLASE; ANTIBIOTIC AGENT; BICARBONATE; CALCIUM; CANAGLIFLOZIN; CREATININE; GLUCOSE; HYPERTENSIVE FACTOR; INSULIN; LEVOTHYROXINE; METFORMIN; SODIUM CHLORIDE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ACIDEMIA; ACIDOSIS; ACUTE PANCREATITIS; ADULT; AFRICAN AMERICAN; AMYLASE BLOOD LEVEL; ANION GAP; APACHE; ARTERIAL GAS; ARTICLE; ASCITES; CALCIUM BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; EXTUBATION; FEMALE; FEVER; FLUID RESUSCITATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; INTUBATION; KETONURIA; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; NAUSEA; TACHYCARDIA; TACHYPNEA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINE VOLUME; VOMITING;

EID: 84936777718     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S86641     Document Type: Article

References (19)

1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–1187.e1–3.
2. Forsmark CE, Baillie J; AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132(5):2022–2044.
3. Spanier BW, Tuynman HA, van der Hulst RW, Dijkgraaf MG, Bruno MJ. Acute Pancreatitis and Concomitant Use of Pancreatitis-Associated Drugs. Am J Gastroenterol. 2011;106(12):2183–2188.
4. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823–837.
5. Cohen D. Reports of pancreatitis are 20–30 times more likely with GLP-1 drugs, analysis finds. BMJ. 2013;346:f2607.
6. American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37 Suppl 1:S14–S80.
7. US Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes [press release]. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed February 22, 2015.
8. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559.
9. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–672.
10. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of Canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
11. Valentine V, Hinnen D. Clinical implications of canagliflozin treatment in patients with type 2 diabetes. Clin Diabetes. 2015;33(1):5–13.
12. Invokana® (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014.
13. Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophyiol. 2014;5(4):405–415.
14. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5(6):648–651.
15. Verma R. Canagliflozin-Associated Acute Pancreatitis. Am J Ther. Epub 2014 Sep 2.
16. Fimognari FL, Corsonello A, Pastorell R, Antonelli-Incalzi R. Metformin-induced pancreatitis. Diabetes Care. 2006;29(5):1183.
17. Alsubaie S, Almalki MH. Metformin induced acute pancreatitis. Dermatoendocrinol. 2013;5(2):317–318.
18. Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000;95(10):2795–2800.
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.